Plain-English translation of NCT06578702 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to learn more about intermittent triple therapy — a treatment approach where people living with HIV take medication on a schedule that's less frequent than daily dosing. This study will review the medical records of adults in Strasbourg, France who have already tried this approach, to understand how well it works and how safe it is in real-world practice.
A previous clinical trial showed that intermittent triple therapy might be effective, but there's very little real-world information about whether this approach actually works well outside of controlled research settings. Some hospitals in France now offer this option, but it's not yet recommended internationally. This study aims to fill that gap by examining actual patient experiences.
You likely qualify if…
You likely don't qualify if…
You would not need to attend visits or take any new medication. Instead, researchers would review your existing medical records from your care at the clinic to see how the intermittent treatment worked for you, how well you tolerated it, and what happened to your health during this time. The study is based entirely on information already collected as part of your routine HIV care.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
France
Enrollment target
~200 participants
Started
February 2024
Primary completion
February 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Axel URSENBACH, MD
University Hospital, Strasbourg, France
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.